Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Takashi Seto

Showing results (231-240 of 242) with videos related to

Pageof 25
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2020
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid TumorsKyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, et al.
Oncotarget|May 10, 2014
Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group studyIsamu Okamoto, Kazuko Sakai, Satoshi Morita, et al.
Cancer Science|October 24, 2021
Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapyToshiaki Takahashi, Kazuko Sakai, Hirotsugu Kenmotsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
Cancer Medicine|May 22, 2023
Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small-cell lung cancer patientsYuka Oku, Gouji Toyokawa, Sho Wakasu, et al.
The Lancet. Oncology|October 3, 2024
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trialJürgen Wolf, Maximilian Hochmair, Ji-Youn Han, et al.
International Journal of Clinical Oncology|May 4, 2019
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IVHiroaki Akamatsu, Kiichiro Ninomiya, Hirotsugu Kenmotsu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2021
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort studyKentaro Ito, Takeharu Yamanaka, Hidetoshi Hayashi, et al.
The New England Journal of Medicine|September 3, 2020
Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung CancerJürgen Wolf, Takashi Seto, Ji-Youn Han, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trialsAlexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
Pageof 25

Showing results (231-240 of 242) with videos related to

Sort By:
Pageof 25
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 28, 2020
U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid TumorsKyriakos P Papadopoulos, Erkut Borazanci, Alice T Shaw, et al.
Oncotarget|May 10, 2014
Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group studyIsamu Okamoto, Kazuko Sakai, Satoshi Morita, et al.
Cancer Science|October 24, 2021
Predictive value of EGFR mutation in non-small-cell lung cancer patients treated with platinum doublet postoperative chemotherapyToshiaki Takahashi, Kazuko Sakai, Hirotsugu Kenmotsu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2022
Updated Integrated Analysis of the Efficacy and Safety of Entrectinib in Patients With NTRK Fusion-Positive Solid TumorsGeorge D Demetri, Filippo De Braud, Alexander Drilon, et al.
Cancer Medicine|May 22, 2023
Impact of the pretreatment prognostic nutritional index on the survival after first-line immunotherapy in non-small-cell lung cancer patientsYuka Oku, Gouji Toyokawa, Sho Wakasu, et al.
The Lancet. Oncology|October 3, 2024
Capmatinib in MET exon 14-mutated non-small-cell lung cancer: final results from the open-label, phase 2 GEOMETRY mono-1 trialJürgen Wolf, Maximilian Hochmair, Ji-Youn Han, et al.
International Journal of Clinical Oncology|May 4, 2019
The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IVHiroaki Akamatsu, Kiichiro Ninomiya, Hirotsugu Kenmotsu, et al.
European Journal of Cancer (Oxford, England : 1990)|January 24, 2021
Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort studyKentaro Ito, Takeharu Yamanaka, Hidetoshi Hayashi, et al.
The New England Journal of Medicine|September 3, 2020
Capmatinib in <i>MET</i> Exon 14-Mutated or <i>MET</i>-Amplified Non-Small-Cell Lung CancerJürgen Wolf, Takashi Seto, Ji-Youn Han, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trialsAlexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
Pageof 25